Modulation of Gi Proteins in Hypertension: Role of Angiotensin II and Oxidative Stress

Madhu B. Anand-Srivastava*

Department of Physiology, Faculty of Medicine, University of Montreal, Québec, Canada

Abstract: Guanine nucleotide regulatory proteins (G-proteins) play a key role in the regulation of various signal transduction systems including adenylyl cyclase/cAMP and phospholipase C (PLC)/phosphatidyl inositol turnover (PI). These are implicated in the modulation of a variety of physiological functions such as platelet functions, cardiovascular functions, including arterial tone and reactivity. Several abnormalities in adenylyl cyclase activity, cAMP levels and G proteins have shown to be responsible for the altered cardiac performance and vascular functions observed in cardiovascular disease states. The enhanced or unaltered levels of inhibitory G-proteins (Gia-2 and Gia-3) and mRNA have been reported in different models of hypertension, whereas Gsa levels were shown to be unaltered. These changes in G-protein expression were associated with Gi functions. The enhanced levels of Gia proteins precede the development of blood pressure and suggest that overexpression of Gi proteins may be one of the contributing factors for the pathogenesis of hypertension. The augmented levels of vasoactive peptides, including angiotensin II (AngII), were shown to contribute to enhanced expression of Gia proteins and associated adenylyl cyclase signaling and thereby increased blood pressure. In addition, enhanced oxidative stress in hypertension due to Ang II may also be responsible for the enhanced expression of Gia proteins observed in hypertension. The mechanism by which oxidative stress enhances the expression of Gi proteins appears to be through the activation of mitogen activated protein (MAP) kinase activity.

Keywords: G-proteins, Angiotensin II, oxidative stress, MAP kinase, adenylyl cyclase, hypertension.

INTRODUCTION

Guanine nucleotide regulatory proteins (G-proteins) are a family of guanosine triphosphate (GTP) binding proteins that play a key regulatory role as transducers in a variety of signal transduction systems. These include adenylyl cyclase/cAMP system [1], the receptor-mediated activation of phospholipase C and A2 [2,3] and a number of hormone-and neurotransmitter-regulated ionic channels [4,5]. G proteins are heterotrimeric proteins composed of three distinct subunits; α, β and γ [6]. The α-subunits bind and hydrolyse GTP and confer specificity in receptor and effector interactions [6]. The GDP bound form of α binds tightly to βγ and is inactive, whereas the GTP bound form of α dissociates from βγ and serves as a regulator of effector proteins. All α-subunits possess intrinsic GTPase activity and hydrolyse the terminal phosphate of bound GTP to yield bound GDP and free inorganic phosphate (Pi). Upon hormone binding and receptor activation, the receptor interacts with the heterotrimeric protein to promote a conformational change and dissociation of bound GDP from the guanine nucleotide binding site. GDP is released and replaced by GTP. Binding of GTP to α induces a conformational change and promotes the dissociation of hormone receptor complex (HR) and the holo G protein into α and βγ. Both α-GTP and βγ subunits can interact with effectors. This activation cycle is terminated by intrinsic GTPase activity of α-subunit. The GDP-bound form of α-subunit has high affinity for βγ and then reassociates with the βγ dimmer to form the heterotrimer in the basal resting state. The family of G-protein α-subunits can be subclassified according to functional or structural relationship. More than 20 mammalian Gα gene products and several alternatively spliced isoforms have been identified. These can be divided into four major subfamilies according to amino acid homology and are represented by Gsa, Gia, Gqa/β11 and α12/α13. The G proteins Gsa and Gia are implicated in the regulation of adenylyl cyclase/cAMP signal transduction system.

The hormone-sensitive adenylyl cyclase system is composed of three components: the receptor, the catalytic subunit, and G-proteins – stimulatory (Gs) and inhibitory (Gi). Molecular cloning has revealed four different forms of Gsa having molecular weights of 45, 45, 52 kDa resulting from the different splicing of one gene [7-9]. Gsa is positively coupled to adenylyl cyclase and mediates the stimulatory responses of hormones on adenylyl cyclase [10,11]. The Gs-mediated activation of adenylyl cyclase results in the increase formation of cAMP. cAMP activates cAMP-dependent protein kinase A that induces the phosphorylation of contractile filaments, sarcosomall and sarcoplasmic proteins, and regulates intracellular calcium homeostasis [12]. In addition, Gsa was also shown to open the Ca2+ channels directly by a cAMP-independent mechanism [13]. In contrast, Gia protein is associated with adenylyl cyclase inhibition [10,11]. Three distinct forms of Gia, namely, Gia1, Gia2, and Gia3 have been cloned and encoded by three distinct genes [14-16]. All three forms of Gia (Gia1-3) have been shown to be implicated in adenylyl cyclase inhibition [17] and activation of atrial Ach-K+ channels [18]. Both the Gα and Gβγ dimer mediate G-protein signaling. Five different β subunits of 35-36 kDa and 12 γ subunits of 8-10 kDa have been identified by molecular cloning. The βγ dimer is tightly

*Address correspondence to this author at the Department of Physiology, Faculty of Medicine, University of Montreal, Québec, Canada; H3C 3J7; Tel: (514) 343-2091; Fax: (514) 343-2111; E-mail: madhu.anand-srivastava@umontreal.ca

© 2010 Bentham Science Publishers Ltd.
associated with GDP bound chain and facilitate the interaction of G-protein with a receptor molecule. The effectors regulated by Gβγ include K⁺ channels, phospholipase C-β, and adenylyl cyclase [19-21].

G-protein α-subunits also possess specific residues that can be covalently modified by bacterial toxins. Cholera toxin catalyzes the transfer of ADP-ribose moiety of NAD to a specific arginine residue in certain α-subunits, whereas pertussis toxin ADP-ribosylates those α-subunits that contain a specific cysteine residue near to the carboxy terminus. Modification of α-subunit by cholera toxin persistently activates these protein by inhibiting their GTPase activity, whereas pertussis toxin inactivates Giα protein and thereby results in the uncoupling of receptor from the effector.

G-PROTEINS AND MEMBRANE SIGNALING IN CARDIOVASCULAR DISEASE

A number of cardiovascular diseases states that eventually result in chronic congestive heart failure are associated with alterations in cardiac performance. Several hormonal factors such as angiotensin II, endothelin and alterations in signal transduction mechanisms including adenylyl cyclase and phospholipase C (PLC) have been reported to play an important role in the alterations of cardiac performance [22].

G-PROTEINS AND MEMBRANE SIGNALING IN HYPERTENSION

Alterations in G-protein levels and functions such as altered adenylyl cyclase responsiveness to various agonists have also been demonstrated in cardiovascular and non-cardiovascular tissues from genetic as well as experimental hypertensive rats [23-28].

An overexpression of Giα₂ and Giα₃ proteins as well as their genes was shown in hearts and aorta from spontaneously hypertensive rats (SHRs), deoxycorticosterone acetate (DOCA)-salt hypertensive rats (HR), N-[Ω-methyl]-L-arginine methyl ester, (L-NAME) HR and 1 kidney 1 clip (1K1C) HR [23-33], whereas Gα protein and its gene was not altered in SHRs, 1K1C and L-NAME HR, and was decreased in DOCA-salt HRs [23-25,28,31-33]. In addition, the levels of Gαo in hearts from SHR were unaltered [24]. Alterations in Gi-protein levels have been shown to be reflected in altered responsiveness of adenylyl cyclase to stimulatory and inhibitory hormones in SHRs, and experimental models of hypertensive rats [24,26,27,31-33]. However, a decreased expression of Giα proteins was also shown in different tissues from different model of SHR including Milan hypertensive rats (MHS) [34-36]. The VSMC from MHS exhibit enhanced basal adenylyl cyclase activity as compared to control normotensive rats (MNS). The number of β-adrenoceptors and the stimulations exerted by isoproterenol and prostaglandin E1 (PGE₁) were significantly increased in MHS than in MNS. On the other hand, platelets from SHRs [26] as well as from hypertensive patients [37] exhibited a decreased expression of Giα₂ and Giα₃ protein as compared to Wistar-Kyoto (WKY) and to normotensive control subjects, respectively whereas the levels of Gαo protein were not altered. The decreased expression of Giα₂ and Giα₃ was correlated with adenylyl cyclase inhibition by inhibitory hormones. The ANP and Ang II-mediated inhibitions were completely attenuated in platelets from SHRs and hypertensive patients, whereas the stimulatory effects of PGE₁, NECA and forskolin were augmented [26,37]. However, McLellan et al. [38] were unable to show any changes in the levels of Gα, Giα₂ and Gβ in platelets from hypertensive patients as compared to normotensive subjects, whereas an enhanced stimulation of adenylyl cyclase by PGE₁ was observed in hypertensive patients as compared to normotensive subjects. On the other hand, lymphocytes from SHRs [39] and hypertensive patients [40] showed a decreased responsiveness of adenylyl cyclase to stimulatory hormones, which may be attributed to the alterations in Gis and Gi proteins. The potentiation of stimulatory responses of several hormones on adenylyl cyclase has also been demonstrated in platelets and splenocytic membranes from SHRs [41,42]. In addition, antihypertensive drug therapy (a combination of β-blockers Ca²⁺ channel blocker, ACE inhibitor, etc.) partially restored Giα₂ levels and the enhanced stimulations exerted by hormones toward normotensive subjects [37]. These effects on platelet function may underlie the beneficial effects of antihypertensive agents on some of the complications of hypertension.

In addition, the levels of Gα, Giα₁, giα₂, Goα, and Giβ were also shown to be unaltered in myocardium from SHRs, whereas hormonal stimulations of adenylyl cyclase were reduced in SHRs, and FSK-stimulated enzyme activity was greater in SHRs as compared to WKY [43]. The reduction in the hormone receptor binding sites may be one of the possible mechanisms responsible for such an impaired response of hormones [44-46]. However, the decreased stimulation of adenylyl cyclase by dopamine D-1 receptors in the kidney tubules from SHRs was shown to be attributed to the defective coupling and not to the changes in the receptor number [47].

Furthermore, the increased levels of Giα were shown to be associated with hypertension and not with hypothyropathy, due to the fact that heart and aorta from Nic-nitro-L-arginine methyl ester-(L-NAME)-induced hypertensive rats, which do not have cardiac hypertrophy exhibited enhanced levels of Giα₂ and Giα₃ proteins as well as mRNA, whereas the levels of Gαo protein were unaltered [31]. The increased levels of Giα₂ and Giα₃ proteins and their mRNA in heart and aorta precedes the development of blood pressure in SHRs [48], and in DOCA-salt hypertensive rats [49], and suggest that the enhanced levels of Giα proteins which result in the decreased levels of cAMP may be one of the contributing factors in the pathogenesis of hypertension. This was further supported by the recent studies showing that the inactivation of Giα protein in prehypertensive rats (2 week old SHR) by a single injection of pertussis toxin (PT) (1.5 μg/100 gm body weight) prevented the development of high blood pressure which was associated with PT-induced decreased levels of Giα proteins [50]. Furthermore, Triggle et al. [51] have also shown that treatment of the SHRs (adult) with PT lowered blood pressure.

ROLE OF ENDOGENOUS ANGIOTENSIN II IN ENHANCED EXPRESSION OF GI PROTEINS IN HYPERTENSION

The levels of vasoactive peptides such as angiotensin II (Ang II), endothelin (ET-1) and arginine vasopressin (AVP),
as well as growth factors that have been reported to be augmented in various models of hypertension [52-60], may be responsible for the enhanced expression of Giα proteins in hypertension. In this regard, a role of Ang II in enhanced expression of Giα protein in SHR and 1K1C hypertensive rats (HR) has been suggested by the studies showing that captopril, an angiotensin converting enzyme (ACE) inhibitor treatment of the SHR and 1K1C HR that decreased the blood pressure also restored the enhanced levels of Giα protein to control levels (Fig. 1). Similarly, the increased blood pressure and enhanced expression of Giα proteins in L-NAME hypertensive rats was also shown to be restored to control levels by losartan, an AT1 receptor antagonist (Fig. 1) suggesting the implication of Ang II in increased levels of Giα proteins and increased blood pressure in L-NAME-induced hypertension. These treatments were also shown to restore the diminished stimulation of adenylyl cyclase by stimulatory hormones and enhanced inhibition by inhibitory hormones observed in SHRs, 1K1C and L-NAME HR [32, 61,62]. In addition, infusion of Ang II in rats that increased blood pressure has also been reported to enhance the levels of Giα proteins [63]. Similarly, nitrendipin and fosinopril treatments have also been reported to have similar effects on Giα proteins and functions in hearts from SHRs [64] and further support the implication of Ang II in enhanced levels of Giα protein in SHR.

**ROLE OF OXIDATIVE STRESS IN ENHANCED EXPRESSION OF GI PROTEINS IN HYPERTENSION**

Reactive oxygen species (ROS) such as O₂⁻, OH⁻ and H₂O₂ that cause oxidative stress have been shown to play a major role in the pathophysiology of cardiovascular diseases including hypertension [65]. NADPH oxidase is the enzyme responsible for the formation of O₂⁻ from the O₂ molecule. Vascular NADPH oxidase is multimeric protein complex composed of at least 4 components: cell membrane-associated p22phox and gp91phox (or gp91phox [Nox2] homologues, nox1 and nox4), and cytosolic subunits, p47phox and p67phox [66,67]. The levels of ROS, have been shown to be augmented in spontaneous (genetic) SHR and experimental hypertension as well as in patients with various hypertensive disorders [68-76]. In addition, the enhanced expression of different subunits of NADPH oxidase such as p47phox, Nox4, p2phox that has been shown in several tissues from SHR [72, 75,76], appear to be responsible for the enhanced activity of NADPH oxidase and ROS production in SHR.

We showed recently that VSMC from SHR exhibit enhanced levels of O₂⁻ [77] which were attenuated by AT1 receptor antagonist, losartan (Fig. 2). In addition, the expression of p47phox and Nox2 was also augmented in these cells as shown in Fig. (3) [78]. Ang II, whose levels are augmented in hypertension, has been shown to be one of the important factors in the regulation of ROS production in SHR.

**Fig. (1).** Effect of Captopril and losartan treatment on blood pressure and the expression of Gi proteins in different models of hypertensive rats (HR). 12 week-old SHR and age-matched WKY rats, 1 kidney 1 clip hypertensive rats (1K1C HR) were treated with captopril (150mg/kg B.W/day) as described earlier [32,61] whereas L-NAME-induced hypertensive rats were treated with losartan (10mg/kg B.W/day) as described earlier [62]. The blood pressure was monitored by the tail cuff method. The expression of Giα-2 and Giα-3 protein in heart from SHR and L-NAME HR and aorta from 1K1C HR were determined by Western blotting using antibodies AS/7 and EC/1 against Giα-2 and Giα-3 protein respectively. The blots are representative of 4 separate experiments. **P<0.01, ***P<0.001 vs control/WKY, ††P<0.01, †††P<0.001 vs SHR/1K1C/L-NAME.
Modulation of Gi proteins in Hypertension: Role of Angiotensin II and Oxidative Stress

Factors regulating NADPH oxidase. In this regard treatment of A10 VSMC with AngII has been shown to augment the production of $O_2^-$ and the expression of Nox4 and p47phox proteins of NADPH oxidase [79]. In addition, we also showed that the enhanced levels of Giα proteins in SHR may also contribute to the enhanced production of $O_2^-$ and increased NADPH oxidase activity, because pertussis toxin treatment of VSMC from SHR also attenuated the enhanced levels of $O_2^-$ and enhanced activity of NADPH oxidase to control WKY levels as shown in Fig. (4) [78]. Furthermore, the decreased levels of cAMP in VSMC from SHR have also been reported to contribute to the enhanced production of $O_2^-$ and increased activity of NADPH oxidase because the treatment of VSMC from SHR with 8Br-cAMP, as well as with cAMP elevating agents such as isoproterenol and forskolin (FSK), restored the enhanced activity of NADPH oxidase and enhanced levels of $O_2^-$ (Fig. 5) and p47phox and Nox4 to control WKY levels (Fig. 6). In addition, a role of reduced levels of cAMP in enhanced oxidative stress was further supported by the fact that Ang II-evoked enhanced production of $O_2^-$, NADPH oxidase activity and enhanced levels of p47phox and Nox4 proteins were shown to be restored to control levels by 8Br-cAMP in A10 VSMC [80].

The role of MAP kinase and PI3K signaling in Ang II-induced enhanced levels of Giα proteins has also been reported [79, 81]. In addition, MEK inhibitor PD98059 (Fig. 7) as well as antioxidants such as diphenyleneiodonium (DPI) and N-acetyl cysteine (NAC) (Fig. 8) were also shown to restore the enhanced levels of Giα proteins in SHR to control levels.
Fig. (4). Effect of pertussis toxin treatment on superoxide anion ($O_2^-$) production (A) and NADPH oxidase activity (B) in vascular smooth muscle cells (VSMC) from 12-week-old spontaneously hypertensive rats (SHR) and age-matched Wistar-Kyoto (WKY) rats. VSMC from SHR and WKY rats were pretreated with 0.5 μg/ml pertussis toxin for 24 hr as described earlier [50] and $O_2^-$ production and NADPH oxidase activity was determined as described earlier [78]. Values are mean ± SEM of 3 separate experiments. **p < 0.01, ***p < 0.001 vs WKY, *p < 0.05, **p < 0.01 vs SHR. Adapted from [78].

Fig. (5). Effect of forskolin (FSK), isoproterenol (Iso) and 8Br-cAMP on superoxide anion ($O_2^-$) production in vascular smooth muscle cells (VSMC) from 12-week-old spontaneously hypertensive rat (SHR) and age matched Wistar-Kyoto (WKY) rats. VSMC from SHR and WKY rats were pretreated with FSK (100 μM), Iso (50 μM) and 8Br-cAMP (0.5 mM) for 24 h, and $O_2^-$ production (A) and NADPH oxidase activity (B) was determined as described earlier [80]. Values are mean ± SEM of 3 separate experiments. ***p < 0.001 vs WKY, ##p < 0.01, ###p < 0.001 vs SHR. Adapted from [80].
Fig. (6). Effect of forskolin (FSK), isoproterenol (Iso) and 8Br-cAMP on the levels of Nox4 and p$^{47}_{\text{phox}}$ protein expression in vascular smooth muscle cells (VSMC) from 12-week-old spontaneously hypertensive rats (SHR) and age matched Wistar-Kyoto (WKY) rats. VSMC from SHR and WKY rats were pretreated without (control) or with FSK (100 μM), Iso (50 μM) and 8Br cAMP (0.5 mM) for 24 hr. Membrane proteins (30 μg) were separated and transferred to nitrocellulose, which was then immunoblotted using specific antibodies against Nox4 (N-15, A) and p$^{47}_{\text{phox}}$ (C-20,B) as described earlier [78]. The Dynein or β actin was used to assess the loading of the protein. Immunoblots are representative of 4 separate experiments. Lower panels: the graph shows quantification of protein ratio of Nox4/Dynein (A) or p$^{47}_{\text{phox}}$/β actin bands by densitometric scanning. The results are expressed as percentage of WKY taken as 100%. Values are mean ± SEM of 4 separate experiments. **p < 0.01 vs WKY, #p < 0.05, ## < 0.01 vs SHR. Adapted from [78].
Fig. (7). Effect of PD 98059 on Giα-2 and Giα-3 protein expression in VSMC from 12 week-old SHR and age-matched WKY rats. Confluent VSMC from SHR and WKY rats were treated with or without PD 98059 (10 μM) for 24 hours at 37°C. Membrane proteins (30 μg) were separated and transferred to nitrocellulose, which was then immunoblotted with specific antibodies against Giα-2 (A) and Giα-3 (B) as described earlier [77]. The blots are representative of three separate experiments. The graphs at lower panel show quantification of protein bands by densitometric scanning. The results are expressed as percentage of WKY control which has been taken as 100%. Values are mean ± S.E.M of 5 separate experiments *P < 0.05 , **P<0.01 vs WKY, §P < 0.05 vs SHR. Adapted from [77].

Fig. (8). Effect of N-acetyl-L-cysteine (NAC) and diphenyleneiodonium (DPI) on Giα-2 and Giα-3 protein expression in vascular smooth muscle cells (VSMC) from 12 week-old SHR and age-matched WKY rats. Confluent VSMC from SHR and WKY rats were treated with 20 mM NAC(A) or 10μM DPI(B) for 24 hours at 37°C. Membrane proteins (30 μg) were separated and transferred to nitrocellulose, which was immunoblotted with antibodies AS/7 and EC/1 against Giα-2 and Giα-3 respectively as described earlier [77] The blots are representative of 5 separate experiments. The graphs at lower panel show quantification of protein bands by densitometric scanning. The results are expressed as percentage of WKY control which has been taken as 100%. Values are mean ± S.E.M of 5 separate experiments *P < 0.05 vs WKY, §§P < 0.01 vs SHR. Adapted from [77].
The levels of Gi-2 and Gi-3 proteins and mRNA are increased in hearts and aorta from genetic and experimentally induced hypertensive rats, whereas the levels of Gsα are unaltered in genetic and decreased in experimentally induced hypertensive rats with established hypertrophy. The increased levels of Gi-2 and Gi-3 are associated with increased Gi functions, resulting in greater decreases in cAMP levels, which may partly explain the increased vascular resistance in hypertension. On the other hand, the decreased levels of Gsα and decreased formation of cAMP in hypertension associated with hypertrophy may also contribute to the increased vascular reactivity in hypertension. The increased levels of Gia-2 and Gia-3 may contribute to the pathogenesis of hypertension whereas decreased levels of Gsα may be associated with hypertrophy and not with hypertension. This notion is substantiated by
our recent studies, showing that enhanced expression of Giα-
2 and Giα-3 proteins and mRNA precede the development of
blood pressure. The role of enhanced levels of Gi proteins in
the pathogenesis of hypertension was further supported by
our studies showing that inactivation of Giα proteins by
pertussis toxin treatment in prehypertensive SHR prevented
the development of blood pressure. However, the levels of
Gs were decreased only in 15 weeks of SHRs with estab-
lished hypertrophy. Similarly, L-NAME hypertensive rats
were hypertrophied rats with volume-overload hypertro-
phy, which do not have hypertension, exhibited decreased
levels of Gsα and no augmentation in Giα-2 or Giα-3 pro-
teins. The increased oxidative stress due to enhanced levels
of endogenous vasoactive peptides including AngII through
MAP kinase signaling, may contribute to the augmented
levels of Gi proteins in SHR. Thus, taken together, it can be
concluded that decreased formation of cAMP levels, either
by increased levels and function of Gi or decreased levels of
Gsα and associated functions, may be responsible for the
altered cardiac performance and vascular reactivity in car-
diovascular disease including hypertension.

REFERENCES

[1] Rodbell M, Krans HM, Pohl SL, Birnbaumer L. The glucagon-
sensitive adenylyl cyclase system in plasma membranes of liver ef-
ects of guanylate nucleotides binding to 32P-guanagon. J Biol Chem
1971; 246: 1872-76.

[2] Cockroft S, Gomperts BD. Role of guanine nucleotide binding
protein in the activation of phosphoinositide phosphodiesterase.
Nature 1985; 315: 534-36.

[3] Litosch I, Wallis C, Fain JN. 5-hydroxytryptamine stimulates inosi-
tol phosphate production in a cell-free system from lowly sali-
vary glands. Evidence for a role of GTP in coupling receptor acti-
vation to phosphoinositide breakdown. J Biol Chem 1985; 260:
5464-71.

[4] Breiwieser GE, Szabo G. Uncoupling of cardiac muscarinic and
beta-adrenergic receptors from ion channels by a guanine nucleo-
tide analogue. Nature 1985; 317: 538-40.

[5] Pfaffinger PJ, Martin JM, Hunter DD, Nathanson NM, Hille B.
GTP-binding proteins couple cardiac muscarinic receptors to a K+
channel. Nature 1985; 317: 536-38.

[6] Gilman A. G proteins and dual control of adenylyl cyclase. Cell
1984; 36: 577-79.

[7] Bray P, Carter A, Simons C, et al. Human cDNA clones for four
species of G alphas signal transduct protein. Proc Natl Acad Sci
USA 1986; 83: 8893-97.

[8] Robishaw J, Snigiel MD, Gilman AG. Molecular basis for two
forms of the G protein that stimulates adenylyl cyclase. J Biol
Chem 1986; 261: 9587-90.

[9] Murakami T, Yasuda H. Rat heart cell membranes contain three
substrate for cholina toxin-catalyzed ADP-ribosylation and a single
substrate for pertussis toxin-catalyzed ADP-ribosylation. Biochem
Biophys Res Commun 1988; 138: 1355-61.

[10] Stryer L, Bourne HR. G-proteins: a family of signal transducers.
Ann Rev Cell Biol 1986; 2: 391-419.

[11] Spiegel AM. Signal transduction by guanine nucleotide binding
proteins. Mol Cell Endocrinol 1987; 49: 1-16

[12] Wankerl M, Schwartz, K. Calcium transport proteins in the nonfail-
ing and failing heart: gene expression and function. J Mol Med
1995; 73: 487-93

[13] Yatani A. Brown, AM. Rapid beta-adrenergic modulation of car-
diac calcium channel current by a fast G protein pathway. Science
1989; 245: 71-74.

[14] Ihoh H, Kozasa T, Nagata S, et al. Molecular cloning and sequence
determination of cDNAs for alpha of the guanine nucleotide-
binding proteins Gs, Gi and Go from rat brain. Proc Natl Acad Sci
USA 1986; 83: 3776-86.

[15] Jones DT, Reed RR. Molecular cloning of five GTP-binding pro-
tein cDNA species from rat olfactory neuroepithelium. J Biol
Chem 1987; 262: 14241-49.

[16] Ioh H, Toyama RI, Kozasa TI, Tsukamoto TI, Matsuoka M, Kaziro Y. Presence of three distinct molecular species of G protein:
a subunit structure of rat cDNA and human genomic DNAs. J Biol
Chem 1988; 263: 6656-64.

[17] Wong YH, Conklin BB, Bourne HR. Gz-mediated hormonal
inhibition of cyclic AMP accumulation. Science 1992; 255:
339-42.

[18] Brown AM, Birnbaumer L. Direct G protein gating of ion chan-
nels. Am J Physiol 1988; 254: H401-H10.

[19] Simon MI, Sraitman MP, Gantam N. Diversity of G proteins in
signal transduction. Science 1991; 252: 802-908.

[20] Tang WJ and Gilman G. Type-specific regulation of adenylyl
cyclase by G protein beta gamma subunits. Science 1991; 254:
1500-03.

[21] Wickman KD, Iniguez Lluhl JA, Davenpot PA, et al. Recombi-
nant G-protein beta gamma-subunits activate the muscarinic-gated
atrial potassium channel. Nature 1994; 368: 255-57.

[22] Brodle OE, Michel MC, Zerkowski HR. Signal transduction
mechanisms controlling cardiac contractility and their alterations
in chronic heart failure. Cardiovasc Res 1995; 30: 570-584

[23] Anand-Srivastava MB. Altered responsiveness of adenylyl cyclase
to adenosine and other agents in the myocardial sarcolemma and
aorta of spontaneously hypertensive rats. Biochem Pharmacol
1988; 37: 3017-22.

[24] Anand-Srivastava MB. Enhanced expression of inhibitory guanine
nucleotide regulatory proteins (Gi) in spontaneously hypertensive
rats: relationship to adenyly cyclase inhibition. Biochem J 1992;
288: 79-85.

[25] Thibault C, Anand-Srivastava MB. Altered expression of G-protein
mRNA in spontaneously hypertensive rat hearts exhibit altered ex-
pression of G-proteins. FEB5 Lett 1992; 313: 160-64.

[26] Anand-Srivastava MB. Rat platelets from spontaneously hyperten-
sive rats exhibit decreased expression of inhibitory guanine nucleo-
tide regulatory protein: relationship with adenyly cyclase activity.
Circ Res 1993; 73: 1032-39.

[27] Anand-Srivastava MB, de Champli J, Thibault C, DOCA-salt
hypertensive rat hearts exhibit altered expression of G-proteins.
Am J Hypertens 1993; 6: 72-75.

[28] Bohm M, Gierschik P, Knorr A, Schmidt U, Weismann K, Erd-
mann E. Cardiac adenylyl cyclase, beta-adrenergic receptors, and G
proteins in salt-sensitive hypertension. Hypertension 1993; 22:
715-27.

[29] Bohm M, Gierschik P, Knorr A, Larisch K, Weismann K, Erdmann
E. Desensitization of adenylyl cyclase and increase of G alpha in
cardiac hypertrophy due to acquired hypertension. Hypertension
1992; 20: 103-12.

[30] Anand-Srivastava MB, Cantin M, Genest J. Altered hormone
sensitivity of adenylyl cyclase in myocardial sarcolemma of renal
hypertensive rats. Biochem Pharmacol 1983; 32: 2857-62.

[31] DiFusco F, Anand-Srivastava MB. Enhanced expression of Gi proteins
in non-hypertrophic hearts from rats with hypertension in-
duced by L-NAME treatment. J Hypertens 2000; 8: 1081-91.

[32] Ge C, Garcia R, Anand-Srivastava MB. Enhanced expression of Gi
protein and adenylyl cyclase activity in hearts from one kidney
one clip hypertensive rats: effect of captoprill. J Hypertens 1999;
17: 1617-25.

[33] Ge C, Garcia R, Anand-Srivastava MB. Enhanced expression of
Gi proteins and adenylyl cyclase signalling in aortas from 1 kid-
ney 1 clip hypertensive rats. Can J Physiol Pharmacol 2006;
84: 739-46.

[34] Clark MJ, Milligan G, Connell J. Guanine nucleotide regulatory
protein alterations in the Milan hypertensive rat strain. J Hypertens
1993; 11: 1161-69.

[35] Michel MC, Farre W, Endrllbrgger W, Philippes A, Brodlle OE.
Ontogenesis of sympathetic responsiveness in spontaneously
hypertensive rats. II. Renal G proteins in male and female rats.
Hypertension 1994; 23: 653-58.
Modulation of Gi proteins in Hypertension: Role of Angiotensin II and Oxidative Stress

Current Cardiology Reviews, 2010, Vol. 6, No. 4  307

[36] Kanagy NL, Webb RC. Increased responsiveness and decreased expression of G-proteins in deoxycorticosterone-salt hypertension. Hypertension 1996; 27: 740-45.

[37] Marcil J, Schiffrin EL, Anand-Srivastava MB. Aberrant adenylyl cyclase/cAMP signal transduction and G protein levels in platelet from hypertensive patients improve with antihypertensive drug therapy. Hypertension 1996; 28: 83-90.

[38] McLellan AR, Milligan G, Houssay MD, Connell JM. G-proteins in essential hypertension: a study of human platelets plasma membranes. J Hypertens 1993; 11: 543-49.

[39] Marcil J, Anand-Srivastava MB. G protein alterations in lymphocytes from spontaneously hypertensive rats: correlation with adenylyl cyclase. Cardiovasc Res 2001; 49: 234-43.

[40] Feldman RD, Jan CM, Chorazyczezki J. G protein regulation in hypertension and aging. Hypertension 1995; 26: 725-32.

[41] Hamet P, Franks DJ, Adnot S, Coquil JF. Cyclic nucleotides in hypertension. Adv Cycl Nucleotide Res 1980; 12: 11-23.

[42] Zeng YY, Benishin CG, Pank PKT. Increased responsiveness of the adenylylate cyclase (AC) signalling system in splenocyte membranes from spontaneously hypertensive rats (SHR) (abstract). FASEB J 1991; 5: A1597.

[43] Anand-Srivastava MB. Altered responsiveness of adenylyl cyclase to adenosine and other agents in the myocardial sarcolemma and aorta of spontaneously hypertensive rats. Biochem Pharmacol 1988; 37: 3017-22.

[44] Limas CJ, Limas C. Reduced number of β-adrenergic receptors in the myocardium of spontaneously hypertensive rats. Biochem Biophys Res Commun 1978; 83: 710-14.

[45] Woodcock EA, Farder JW, Johnston CI. Decreased cardiac beta-adrenergic receptors in deoxycorticosterone-salt and renal hypertensive rats. Circ Res 1979; 45: 560-65.

[46] Bhatta RC, Sharma RV, Raamanathan S. Ontogenetic development of isoproterenol subsensitivity of myocardial adenylyl cyclase class and beta-adrenergic receptors in spontaneously hypertensive rats. Biochem Biophys Acta 1980; 632: 497-506.

[47] Kinoshita S, Ghiidhu A, Felder RA. Defective dopammine-1 receptor adenylcyclase coupling in the proximal convoluted tubule from the spontaneously hypertensive rat. J Clin Invest 1989; 84: 1849-56.

[48] Marcil J, Thibault C, Anand-Srivastava MB. Enhanced expression of Gi protein precedes the development of blood pressure in spontaneously hypertensive rats. J Mol Cell Cardiol 1997; 29: 1008-22.

[49] Marcil J, de Champlain J, Anand-Srivastava MB. Overexpression precedes the development of DOCA-salt-induced hypertension: relationship with adenyl cyclase. Cardiovasc Res 1998; 39: 492-505.

[50] Li Y. Anand-Srivastava MB. Inactivation of Gi proteins by pertussis toxin attenuated the development of hypertension in spontaneously hypertensive rats. Circ Res 2002; 91: 247-54.

[51] Trigg RR, Tabrizchi R. Changes in vascular smooth muscle function in hypertension. Clin Med J 1993; 106: 250-57.

[52] Morishita K, Migaki J, Migozaki, Ogihani T. Possible role of vascular renin angiotensin system in hypertension and vascular hypertrophy. Hypertension 1992; 19: 62-67.

[53] Trimder D, Philpips RA, Risvani J, Stephenson JM, Johnston CI. Regulation of vasopressin receptor in deoxycorticosterone acetate salt hypertension. Hypertension 1992; 20: 569-74.

[54] Wabolander HA, Wickman A, Isgaard J, Frigeri P. Interaction between renin-angiotensin system and insulin-like growth factor-1 in aorta-caval fistula. Acta Physiol Scan 1999; 165: 143-54.

[55] Kagiyma S, Eguchi S, Frank GD, Inagani T, Zhang YC, Philpips MI. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 2002; 106: 909-12.

[56] Iglarz M, Schiffrin EL. Role of endothelin-1 in hypertension. Curr Hypertens Rep 2003; 5: 144-48.

[57] Kagiyma S, Qian K, Kagiyma T, Philpips MI. Antisense to epidermal growth factor receptors prevents the development of left ventricular hypertrophy. Hypertension 2003; 41: 824-29.

[58] Kirchhast M, Witte K, Stolpe K, Schilling L, Nedevsky PI, Schmidt HH , Lemmer B. Effects of chronic endotelin ET(A) receptor blockade on blood pressure and vascular formation of cyclic guanosine 3’5’ monophosphate in spontaneously hypertensive rats. Arzneimittelforschung 2005; 55: 498-504.

[59] Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Sayai R, Roth M, Sydkov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-21.

[60] Jesnun S, Zaedi S, Maeda S, et al. Endothelin antagonism suppresses plasma and cardiac endothelin-1 levels in SHR SPs at the typical hypertensive stage. Exp Biol Med 2006; 231: 919-24.

[61] Pandey S, Anand-Srivastava MB. Modulation of G-protein expression by the angiotensin converting enzyme inhibitor captopril in hearts from spontaneously hypertensive rats: relationship with adenylyl cyclase. Am J Hypertens 1996; 9: 833-37.

[62] Hashmi S, Anand-Srivastav MB. Losartan-induced attenuation of blood pressure in L-NAME hypertensive rats is associated with reversal of the enhanced expression of Gi protein. J Hypertens 2004; 22: 181-90.

[63] Sims C, Ashby K, Douglas JG. Angiotensin II-induced changes in guanine nucleotide binding and regulatory proteins. Hypertension 1992; 19: 146-52.

[64] Bohm M, Kirchmayer R, Erdmann E. Myocardial Gi alpha-protein levels in patients with hypertensive cardiac hypertrophy, chronic heart disease and cardiogenic shock. Cardiovasc Res 1995: 30: 611-18.

[65] Abe, JI, Berk BC. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardiovasc Med 1998; 7: 59-64.

[66] Lassegue B, Clempus, RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003; 285: R277-R297.

[67] Touyz RM , Tabet F, Schiffrin, EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 2003; 30: 860-66.

[68] Zalba G., Beaumont FJ, San Jose G, et al. Vascular NADH/NADP oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 2000; 35: 1055-61.

[69] Park JB, Touyz R.M., Chen X., Schiffrin E.L. Chronic treatment with a superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am. J. Hypertens. 2002; 15: 78-84.

[70] Hijashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346: 1954-62.

[71] Chouhazoti T, Tojo A, Wilecox CS. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 2002; 39: 269-74.

[72] Paravicini TM., Chrissobolos S, Drummond GR., Sobe CY. Increased NADH-oxidase activity and Nox4 expression during chonic hypertensive is associated with enhanced cerebral vasodilatation to NADPH in vivo. Stroke 2004; 35: 585-89.

[73] Tanito M, Nakamura H, Kwon YW, et al. Enhanced oxidative stress and impaired thiredoxin expression in spontaneously hypertensive rats. Antioxid Redox Signal 2004; 6: 89-97.

[74] Ward NC, Hodgson M, Puddey IB, Mori TA, Beilin LJ, Croft KD. Oxidative stress in human hypertension: association with anti-hypertensive treatment, gender, nutrition, and lifestyle. Free Radic Biol Med 2004; 36: 226-34.

[75] Lodis F, Gogolludo A, Durate J, et al. Increased NADPH oxidase activity mediates spontaneous arterial tone in genetically hypertensive rats. Eur J Pharmacol 2006; 544: 97-103.

[76] Sanchez M, Galistio M, Vera R, et al. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 2006; 24: 75-84.

[77] Lappas G, Bou Daou G, Anand-Srivastava MB. Oxidative stress contributes to the enhanced expression of Gialpha proteins and adenylyl cyclase signaling in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens 2005; 23: 2251-61

[78] Saha S, Li Y, Lappas G, Anand-Srivastava MB. Activation of natriuretic peptide receptor-C attenuates the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hyper-
tensive rats: implication of Gi alpha protein. J Mol Cell Cardiol 2008; 44: 336-44.

[79] Li Y, Lappas G, Anand-Srivastava MB. Role of oxidative stress in angiotensin II-induced enhanced expression of Gi(alpha) proteins and adenyl cyclase signaling in A10 vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2007; 292: H1922-H1930.

[80] Saha S, Li Y, Anand-Srivastava, MB. Reduced levels of cyclic AMP contribute to the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive rats Can J Physiol Pharmacol 2008; 86: 190-8.

[81] Ge C, Anand-Srivastava MB. Involvement of phosphatidyl inositol-3-kinase and mitogen-activated protein kinase in AII-mediated enhanced expression of Gi proteins in vascular smooth muscle cells. Biochem Biophys Res Commun 1998; 251: 570-75.